# A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia

> **NCT01034410** · PHASE2 · TERMINATED · sponsor: **Antisoma Research** · enrollment: 90 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** AS1411
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT01034410
- **Lead sponsor:** Antisoma Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2011-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01034410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01034410, "A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01034410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*